Evidence map›Paper›PMID 39004442›Full record

Trial reportBMJ sexual & reproductive health2025

Double dosing ulipristal acetate emergency contraception for individuals with obesity: a randomised crossover trial.

Alison Edelman, Jon D Hennebold, Kise Bond, Jeong Y Lim, Ganesh Cherala, Steven W Blue, Shawn P Kraft, David W Erikson, David Archer, Jeffery Jensen

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ sexual & reproductive health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alison EdelmanDepartment of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon, USA edelmana@ohsu.edu.ORCID http://orcid.org/0000-0001-5040-7288
Jon D HenneboldDepartment of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon, USA.
Kise BondDepartment of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon, USA.
Jeong Y LimBiostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Ganesh CheralaClinical Pharmacology, Nurix Therapeutics, San Francisco, California, USA.
Steven W BlueEndocrine Technologies Core, Oregon Primate National Research Center, Beaverton, Oregon, USA.
Shawn P KraftEndocrine Technologies Core, Oregon Primate National Research Center, Beaverton, Oregon, USA.
David W EriksonEndocrine Technologies Core, Oregon Primate National Research Center, Beaverton, Oregon, USA.ORCID http://orcid.org/0000-0002-3383-9297
David ArcherClinical Research Center, Department of OB/GYN, Eastern Virginia Medical School, Norfolk, Virginia, USA.
Jeffery JensenDepartment of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon, USA.

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
Improving emergency contraceptive effectiveness in obese womenR01HD089957 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI EDELMAN, ALISON B · 2017 to 2021
$1.7M
Improving Contraceptive Effectiveness in Obese WomenR01HD061582 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI EDELMAN, ALISON B · 2009 to 2010
$1.1M
NCATS NIH HHS UL1 TR002369NICHD NIH HHS R01 HD061582NICHD NIH HHS R01 HD089957NIH HHS P51 OD011092
6 · The paper itself

Abstract

objectiveTo determine whether increasing the dose of ulipristal acetate (UPA)-containing emergency contraception (EC) improves pharmacodynamic outcomes in individuals with obesity. STUDY

designWe enrolled healthy, regularly-cycling, confirmed ovulatory, reproductive-age individuals with body mass index (BMI) >30 kg/m

resultsWe enrolled a total of 52 participants with BMI >30 kg/m

conclusionA standard 30 mg dose of UPA is sufficient to delay ovulation regardless of BMI or weight. Results of our study do not support dose adjustment for body size.

Indexed as

Contraception, PostcoitalCross-Over StudiesNorpregnadienesObesityAdultBody Mass IndexEstradiolFemaleHumansLuteinizing HormoneProgesteroneYoung AdultEstradiolLuteinizing HormoneNorpregnadienesProgesteroneulipristal acetateemergency contraceptionObesity

Identifiers

PMID39004442
PMCPMC11703681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.